drugset / Trial / NCT04045730
The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label single arm phase 2 study for patients with metastatic pancreatic ductal adenocarcinoma who have not received any prior systemic therapies.
Timeline
- Start
- 2019-11-15
- Primary completion
- 2019-12-31
- Completion
- 2021-07-31
Outcome
Outcome not reported
Stopped: “Halozyme isn't allowing this trial to move forward until their current clinical trial results are released.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Nab-paclitaxel | Small molecule | — | — |
| Subject | PEGPH20 | Protein / enzyme biologic | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |